Anticancer agent composition
US10172835B2 · kind B2 · utility
1Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2014 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | May 1, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y305/01001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating cancer includes administering to a subject in need of the treatment an anticancer agent composition that includes the following agents as active ingredients; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.